Ask about this productRelated genes to: USP22 antibody
- Gene:
- USP22 NIH gene
- Name:
- ubiquitin specific peptidase 22
- Previous symbol:
- USP3L
- Synonyms:
- KIAA1063
- Chromosome:
- 17p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-12-20
- Date modifiied:
- 2014-11-18
Related products to: USP22 antibody
Related articles to: USP22 antibody
- Ubiquitin-specific protease 22, an important catalytic component of the human SAGA (Spt-Ada-GcN5 Acetyltransferase) complex, regulates the deubiquitination and methylation of histones, which in turn influences gene expression. Its overexpression alters gene regulation, transcription, cancer progression, and therapy resistance. Its role is increasingly being noticed in cancers. - Source: PubMed
A Uma DeviShukla Prakash Kumar - Androgen receptor splice variant 7 (AR-V7) is a principal driver of resistance to androgen receptor signaling inhibitors in castration-resistant prostate cancer. By virtue of its truncated ligand-binding domain, AR-V7 functions as a constitutively active transcription factor, sustaining oncogenic signaling independently of androgenic ligands. Its biogenesis is orchestrated by epigenetic regulators and splicing factors, including jumonji domain-containing 6 and eukaryotic translation initiation factor 4A3, which facilitate the production of stabilizing peptides such as that encoded by circSRCAP. AR-V7 establishes a distinct transcriptional programme, frequently cooperating with full-length AR and co-activators like YAP1/TAZ to activate proliferative genes (e.g., UBE2C) and repress tumor suppressors (e.g., SLC22A3). Protein stability is tightly controlled by deubiquitinases USP22 and USP14, while targeted degradation is mediated by the HSP70-STUB1 complex. Clinically, detection of AR-V7 in circulating tumor cells serves as an actionable biomarker, enabling selection of taxane chemotherapy over ineffective androgen receptor signaling inhibitors. Emerging therapeutic strategies include proteolysis-targeting chimaeras, N-terminal domain inhibitors, and agents targeting CDK9 or PRMT1. Overcoming AR-V7-mediated resistance will require deeper biological dissection using single-cell multi-omics and the development of rational combination therapies, representing a pivotal challenge in precision oncology for castration-resistant prostate cancer. - Source: PubMed
Publication date: 2026/05/11
Li JunWang XiongTang Xiaoshuang - Non-small cell lung cancer (NSCLC) remains a prevalent and malignant cancer globally, characterized by chemotherapy resistance. The aim of this study was focused on the potential of ginsenoside (Gn)-Rh2 from ginseng exosomes (Gn-Exos), a primary bioactive constituent of Panax ginseng, to enhance chemotherapy sensitivity in NSCLC. - Source: PubMed
Publication date: 2026/05/09
Liu JiaoWang MenghanXia MaolinYan RuyuXu EntaoSun HangZhong YanpingXu YiZhang ZhouqiutongXue FengfengJin MingmingHuang Qingqing - Ubiquitination plays a crucial role in cancer initiation and development by regulating protein stability and functions. Deubiquitinases (DUBs) are key enzymes in this process, primarily responsible for removing ubiquitin chains from substrate proteins, thereby preventing protein degradation and regulating diverse cellular signaling pathways. Ubiquitin-specific peptidase 22 (USP22), a member of the ubiquitin-specific protease (USP) subfamily of DUBs, critically deubiquitinates histones and various oncogenic proteins such as cellular myelocytomatosis viral oncogene homolog (c-Myc), forkhead box protein 3 (FOXP3), and hypoxia-inducible factor 1-alpha (HIF-1α). USP22 is frequently dysregulated in cancers and associated with tumor progression, cancer stemness, invasion, therapy resistance, and immune evasion. Thus, USP22 has emerged as a promising novel therapeutic target in oncology. Recent studies have demonstrated that inhibition of USP22 can effectively suppress tumor growth, enhance antitumor immune responses, and overcome drug resistance in preclinical models. Nevertheless, the clinical translation of USP22 inhibitors continues to encounter challenges. In this review, we summarize the role of USP22 in cancer and discuss recent progress in developing novel USP22 inhibitors as antitumor agents. - Source: PubMed
Publication date: 2026/04/16
Zhou BaobaoLin ZiyiGuo YongXin WenyuDing JianTang WeiZhang Hefeng - The purpose of this study was to explore the effect of ubiquitin-specific protease (USP) 22 overexpression on spinal cord injury (SCI) in rats and its potential mechanism, to assess its role in the recovery of neurological function. - Source: PubMed
Yu Ming-ChenLi Xiao-LinLu Shuai-JinNing Ming-LiangYan ZhenzhongYang Yadong